Want to see JP:7133 full AI Analyst Report?
HYUGA PRIMARY CARE Co.,Ltd. (7133) AI Stock Analysis
HYUGA PRIMARY CARE Co.,Ltd.
(TSE/TYO:7133)
The overall score reflects strong technical momentum and a fair valuation, balanced against mixed financial health. While revenue scaling is excellent, tightening profit margins and reduced cash flow flexibility present near-term operational challenges.
HYUGA PRIMARY CARE Co.,Ltd. (7133) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 15.03B
- Dividend Yield
- 0.95%
- Average Volume (3M)
- 29.95K
- Price to Earnings (P/E)
- 24.4
- Beta (1Y)
- 0.12
- Revenue Growth
- 22.80%
- EPS Growth
- -10.77%
- Country
- Japan
- Employees
- 882
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
HYUGA PRIMARY CARE Co.,Ltd. Business Overview & Revenue Model
Company Description
HYUGA PRIMARY CARE Co.,Ltd., established in 2007 and based in Kasuga, Japan, specializes in delivering a variety of primary care services, encompassing home-visit pharmacies, nursing support, and personalized care planning. The company extends its ex...
How the Company Makes Money
The company primarily generates revenue through dispensing-pharmacy operations, where it earns fees associated with filling prescriptions issued by medical institutions and receives payment for providing medication guidance and related pharmacy servi...
HYUGA PRIMARY CARE Co.,Ltd. Financial Statement Overview
Summary
Impressive top-line growth and solid return on equity are offset by compressing profit margins, rising debt levels, and a sharp decline in free cash flow generation.
Income Statement
75PositiveBalance Sheet
68PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.68B | 11.98B | 9.98B | 8.29B | 6.66B | 5.78B |
| Gross Profit | 2.38B | 2.25B | 2.41B | 1.88B | 1.56B | 1.24B |
| EBITDA | 1.37B | 1.18B | 1.31B | 854.38M | 627.27M | 568.69M |
| Net Income | 614.95M | 501.88M | 719.03M | 441.03M | 382.88M | 328.45M |
Balance Sheet | ||||||
| Total Assets | 8.67B | 8.29B | 7.05B | 6.35B | 2.92B | 2.54B |
| Cash, Cash Equivalents and Short-Term Investments | 1.24B | 1.02B | 565.93M | 688.01M | 567.69M | 719.56M |
| Total Debt | 2.86B | 3.22B | 2.65B | 2.80B | 251.54M | 330.21M |
| Total Liabilities | 5.90B | 5.56B | 4.68B | 4.71B | 1.44B | 1.46B |
| Stockholders Equity | 2.77B | 2.73B | 2.37B | 1.64B | 1.48B | 1.07B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 35.71M | 485.51M | 473.20M | 102.59M | 228.92M |
| Operating Cash Flow | 0 | 492.94M | 771.32M | 706.64M | 342.25M | 484.60M |
| Investing Cash Flow | 0 | -319.13M | -473.98M | -1.13B | -383.39M | -320.25M |
| Financing Cash Flow | 0 | 281.88M | -419.43M | 538.78M | -110.73M | 16.93M |
HYUGA PRIMARY CARE Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7133, the sentiment is Positive. The current price of 2106.00 is above the 20-day moving average (MA) of 2105.55, above the 50-day MA of 1715.20, and above the 200-day MA of 1257.84, indicating a bullish trend. The MACD of 102.63 indicates Positive momentum. The RSI at 95.10 is Negative, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7133.
HYUGA PRIMARY CARE Co.,Ltd. Peers Comparison
Overall Rating
JP:713372Outperform
JP:707164Neutral
JP:237361Neutral
JP:242556Neutral
JP:706152.1Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | JPY 15.34B | 24.42 | ― | 0.95% | 22.80% | -10.77% | |
| 64Neutral | JPY 37.65B | 11.89 | ― | 1.10% | 6.17% | -33.01% | |
| 61Neutral | JPY 5.14B | 18.16 | ― | 4.43% | 4.76% | -52.55% | |
| 56Neutral | JPY 2.49B | 29.36 | ― | 3.37% | -5.72% | -73.78% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | JPY 3.83B | 11.24 | ― | ― | 14.91% | -39.00% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7133 | HYUGA PRIMARY CARE Co.,Ltd. | 2106.00 | 889.91 | 73.18% | |
| JP:2373 | Care Twentyone Corporation | 384.00 | -46.18 | -10.74% | |
| JP:2425 | Care Service Co., Ltd. | 653.00 | -103.28 | -13.66% | |
| JP:7061 | Japan Hospice Holdings Inc. | 430.00 | -851.94 | -66.46% | |
| JP:7071 | Amvis Holdings.Inc. | 364.00 | -58.69 | -13.88% |
HYUGA PRIMARY CARE Co.,Ltd. Corporate Events
HYUGA PRIMARY CARE Unveils Q1 FY2027 Results and Outlook
HYUGA PRIMARY CARE Co., Ltd. released its financial results for the first quarter of the fiscal year ending March 2027, outlining performance and trends under its TSE Growth Market listing. The disclosure highlights how the quarter’s results fi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 29, 2026